Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects
December 03, 2024 08:15 ET
|
Palisade Bio, Inc.
First three Single Ascending Dose cohorts demonstrated no treatment related adverse events Carlsbad, CA, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,”...
Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)
November 21, 2024 08:15 ET
|
Palisade Bio, Inc.
Data to be presented at the 8th Annual Antifibrotic Drug Development (AFDD) Summit PALI-2108 may offer a solution for fibrostenotic Crohn’s disease by enhancing efficacy, safety, and therapeutic...
Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC)
November 07, 2024 08:30 ET
|
Palisade Bio, Inc.
Carlsbad, CA, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing...
Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis
October 31, 2024 08:30 ET
|
Palisade Bio, Inc.
Targeted, better-tolerated oral PDE4 inhibitors are an unmet need in inflammatory bowel disease (IBD) PALI-2108 demonstrates in ex vivo studies; targeted activation and reduced side effects,...
Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)
October 10, 2024 08:30 ET
|
Palisade Bio, Inc.
– Company has received a No Objection Letter from Health Canada in response to submission of its Phase 1 Clinical Trial Application (CTA) – The study is a Phase 1 Single Ascending Dose (SAD)...
Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis
September 25, 2024 08:00 ET
|
Palisade Bio, Inc.
– Completion of nonclinical safety and toxicity studies, Phase 1 clinical trial design and established Maximum Recommended Starting Dose – Completion of pre- Clinical Trial Application (CTA)...
Palisade Bio Launches New Corporate Branding and Reiterates Commitment to Advancing Next-Generation Precision Therapies
September 16, 2024 08:00 ET
|
Palisade Bio, Inc.
– Company remains committed to its mission to become a leader in developing differentiated product candidates targeting immune, inflammatory and fibrotic diseases – Successful completion of...
Palisade Bio Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis
August 08, 2024 08:00 ET
|
Palisade Bio, Inc.
– Phase 1 human clinical study of PALI-2108 for the treatment of Ulcerative Colitis (UC) on track to commence before year end – Based on the modeling and simulations, Palisade has established dose...
Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108
July 29, 2024 08:30 ET
|
Palisade Bio, Inc.
Findings demonstrate that the microbiome and enzymes are sufficient in mouse, dog, and Normal Healthy Volunteers (NHV) and Ulcerative Colitis (UC) patients Company advancing toward commencement of...
Palisade Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108
July 19, 2024 08:30 ET
|
Palisade Bio, Inc.
Patent includes Composition of Matter claims for both PALI-2108 and PALI-1908 programs Patent includes broad claims for “Gut Microbiota Bioactivated PDE4 Inhibitor Precursors” with similar...